List of bibliographic references
Number of relevant bibliographic references: 4.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 2 | Adult |
| 2 | Aged |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Antineoplastic agent |
| 2 | Chronic myelogenous leukemia |
| 2 | Enzyme inhibitor |
| 2 | Female |
| 2 | Humans |
| 2 | Imatinib |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) |
| 2 | Male |
| 2 | Middle Aged |
| 2 | Nilotinib |
| 1 | Abnormal chromosome C9 |
| 1 | Abnormal chromosome G22 |
| 1 | Adolescent |
| 1 | Aged, 80 and over |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | C-Onc gene |
| 1 | Cardiovascular Diseases (chemically induced) |
| 1 | Cardiovascular Diseases (epidemiology) |
| 1 | Chromosome translocation |
| 1 | Clinical Trials as Topic (methods) |
| 1 | Clinical Trials as Topic (statistics & numerical data) |
| 1 | Comparative study |
| 1 | Dasatinib (adverse effects) |
| 1 | Disease-Free Survival |
| 1 | Drug-Related Side Effects and Adverse Reactions (classification) |
| 1 | Drug-Related Side Effects and Adverse Reactions (pathology) |
| 1 | Early stage |
| 1 | Fusion Proteins, bcr-abl (genetics) |
| 1 | Hematology |
| 1 | Human |
| 1 | Hybrid gene |
| 1 | Imatinib Mesylate (administration & dosage) |
| 1 | Imatinib Mesylate (adverse effects) |
| 1 | Imidazoles (administration & dosage) |
| 1 | Imidazoles (adverse effects) |
| 1 | Incidence |
| 1 | Ischemia (chemically induced) |
| 1 | Ischemia (epidemiology) |
| 1 | Kaplan-Meier Estimate |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics) |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology) |
| 1 | Medicine |
| 1 | Non-specific serine/threonine protein kinase |
| 1 | Outcome Assessment (Health Care) (methods) |
| 1 | Outcome Assessment (Health Care) (statistics & numerical data) |
| 1 | Philadelphia Chromosome (drug effects) |
| 1 | Philadelphia chromosome |
| 1 | Prostatic Neoplasms (drug therapy) |
| 1 | Protein Kinase Inhibitors (adverse effects) |
| 1 | Protein-tyrosine kinase |
| 1 | Pyridazines (administration & dosage) |
| 1 | Pyridazines (adverse effects) |
| 1 | Resistance |
| 1 | Treatment Outcome |
| 1 | Tyrosine kinase inhibitor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Philipp Le Coutre"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Philipp Le Coutre" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Philipp Le Coutre
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
